Who is sponsoring NCT05682885?

NCT05682885 is sponsored by Dharmais National Cancer Center Hospital.

What drugs are being tested in NCT05682885?

Interventions in NCT05682885: Lymphatic Bypass Supermicrosurgery.

What condition does NCT05682885 study?

NCT05682885 studies Breast Cancer Related Lymphedema, Lymphedema Arm.

Is NCT05682885 still recruiting?

NCT05682885 is currently active, enrolled. Last updated 22 January 2025.

Last reviewed 2025-01-22 · How we verify

NCT05682885: ELYBS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effectiveness of Lymphatic Bypass Supermicrosurgery

Active, enrolled NA Last updated 22 January 2025

What this trial tests

NA trial testing Lymphatic Bypass Supermicrosurgery in Breast Cancer Related Lymphedema in 140 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

6 October 2022

Primary endpoint
31 October 2027

18 November 2027

Quick facts

Lead sponsor	Dharmais National Cancer Center Hospital
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	140
Start date	6 October 2022
Primary completion	31 October 2027
Estimated completion	18 November 2027
Sites	1 location across Indonesia

Drugs / interventions tested

Lymphatic Bypass Supermicrosurgery

Conditions studied

Breast Cancer Related Lymphedema — all drugs for Breast Cancer Related Lymphedema →
Lymphedema Arm — all drugs for Lymphedema Arm →

Sponsor

Dharmais National Cancer Center Hospital

Who can join

18 and older, any sex, with Breast Cancer Related Lymphedema or Lymphedema Arm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluate the effectiveness of lymphatic bypass supermicrosurgery (LBS) and axillary lymph node dissection (ALND) compare to ALND alone to prevent breast cancer treatment-related lymphedema (BCRL).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Supermicrosurgery lymphaticovenous and lymphaticolymphatic anastomosis: Technical detail and short-term follow-up for immediate lymphatic reconstruction in breast cancer treatment-related lymphedema prevention.
Brahma B, Yamamoto T, Panigoro SS, Haryono SJ, et al · · 2024 · cited 9× · PMID 38428499 · DOI 10.1016/j.jvsv.2024.101863
The pattern of arm lymphatic drainage and subclinical lymphedema progression after axillary lymph node dissection: a prospective cohort study.
Brahma B, Yamamoto T, Panigoro SS, Haryono SJ, et al · · 2025 · PMID 40865944 · DOI 10.1097/js9.0000000000003252

Verify or expand the search:

Other recruiting trials for Breast Cancer Related Lymphedema

Currently open trials in the same condition.

NCT06697158 — Investigation of the Effects of Complex Decongestive Physiotherapy on Sleep Quality and Quality of Life in Women With Br · NA · recruiting
NCT04665882 — Nomogram to Predict Breast Cancer Related Lymphedema · NA · recruiting

Other Dharmais National Cancer Center Hospital trials

Trials by the same sponsor.

NCT06993740 — Effect of Dexmedetomidine on Microsurgery Reconstruction in Cancer Patient · NA · recruiting
NCT07233863 — Lymphovenous Bypass Procedure for Secondary Prevention of Lymphedema in Breast Cancer · NA · recruiting
NCT07144475 — Comparison of Probiotic Effects on the Outcomes of Patients After Colorectal Cancer Surgery · Phase 4 · completed
NCT07252843 — Integrating Clinical, Protein Expression, and Genetic Markers to Predict Lymphedema in Breast Cancer · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05682885 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dharmais National Cancer Center Hospital
Last refreshed: 22 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05682885.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing